About Olive Capital
Olive Capital (OC) is an early-stage investment firm focused on the tech and synthetic biology sectors. Our portfolio includes diverse companies in these spaces, including Pardes (NASDAQ: PRDS), Akasa, Science, Substack, Ender, Orchid Health, and Rewind. OC builds on the experience of founding partner Olivia Wang, who previously headed up the US office of ZhenFund, managing an AUM of $2 billion and a portfolio of 40+ companies. The combination of our vast VC network and strong founder relationships grants us access to highly competitive investment rounds, to the extent that we are often the sole small fund alongside institutional heavyweights. We take firm evaluation and selection very seriously, pairing in-house research with the expertise of external domain advisors and institutional partners. OC Fund I launched in 2021, and OC Fund II is currently in the pipeline.